Efficacy and Safety of Obeldesivir in High-Risk Nonhospitalized Patients with COVID-19 (BIRCH): a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study

Journal:

Clinical Infectious Diseases

Published:

2025-07-22

DOI:

10.1093/cid/ciaf406

Affiliations:

15

Authors:

24

Go to article

Institutions	Authors	Share
Gilead, United States of America (USA)	13.000000 13.000000	0.54
Vita-Salute San Raffaele University (UniSR), Italy	1.000000	0.04
National Taiwan University (NTU), Taiwan	1.000000	0.04
Kaohsiung Veterans General Hospital, Taiwan	1.000000	0.04
Gilead Sciences Europe Ltd., United Kingdom (UK)	1.000000	0.04
FAICIC Clinical Research, Mexico	1.000000	0.04
Ormeau Clinical Trials, United Kingdom (UK)	1.000000	0.04
Limpopo Clinical Research Initiative (LCRI), South Africa	1.000000	0.04
San Carlos Clinical Hospital (HCSC), Spain	1.000000	0.04
Carol Davila University of Medicine and Pharmacy (UMFCD), Romania	0.500000	0.02
National Institute of Infectious Diseases "Prof. Dr. Matei Bals" (INBIMB), Romania	0.500000	0.02
Köhler and Milstein Research S.A. de C.V, Mexico	0.500000	0.02
Autonomous University of Yucatán (UADY), Mexico	0.500000	0.02
National Cancer Institute (INCA), Brazil	0.500000	0.02
University of São Caetano do Sul (USCS), Brazil	0.500000	0.02

Interested in Medical Microbiology?